Roche throws in the towel on Tecentriq bladder, myeloma trials

Roche’s Tecentriq has scored some important victories lately, including a pair of first-in-class approvals. But in other types of cancer, the Swiss drugmaker has decided to pull the plug.

In a Wednesday update to its pharma pipeline, Roche listed two phase 1 Tecentriq studies—one in non-muscle invasive bladder cancer and one in multiple myeloma—that it had cast aside.